Tumor Biology

, Volume 35, Issue 3, pp 2481–2489 | Cite as

Expression of p53 family genes in urinary bladder cancer: correlation with disease aggressiveness and recurrence

  • Danae Papadogianni
  • Nikolaos Soulitzis
  • Demetrios Delakas
  • Demetrios A. Spandidos
Research Article

Abstract

p53 is a tumour suppressor gene with an established role in the majority of human neoplasias. Its homologues—p63 and p73—cannot be classified as tumour suppressors, since they encode isoforms with oncogenic properties as well. p63 plays a crucial role in epithelial cell differentiation and p73 is essential for neuronal cell development. The p63 and p73 expressions have been investigated in a variety of human tumours including bladder carcinomas; yet, this is the first study to simultaneously analyse the transcriptional levels of all p53 family members in bladder cancer. Using quantitative real-time polymerase chain reaction, we measured the mRNA expression of p53, p63 and p73 in 30 bladder tumours, each paired with adjacent normal tissue. All three studied genes were up-regulated in malignant specimens, p53 by 1.9-fold, p63 by threefold and p73 by twofold, respectively. Further analysis suggested that p63 and p73 act independently of p53 in the malignant bladder epithelium. Statistical analysis revealed that p63 overexpression was more frequent in recurrent bladder tumours (p = 0.045) and in older patients (p = 0.022). Papillary tumours also exhibited abnormal p63 expression (p = 0.026). Finally, p73 was up-regulated in Grade III one-site tumours (p = 0.040). Our results indicate that all p53 family members are abnormally expressed in bladder cancer but do not act synergistically. High levels of p63 correlate with non-muscle invasive tumours with frequent relapses, whereas p73 overexpression is associated with a more aggressive tumour phenotype.

Keywords

p63 p73 Real-time PCR mRNA Bladder cancer Biomarkers 

Notes

Conflicts of interest

None

References

  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRefGoogle Scholar
  2. 2.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.PubMedCrossRefGoogle Scholar
  3. 3.
    Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2005;66:4–34.PubMedCrossRefGoogle Scholar
  4. 4.
    Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer. 2005;5:713–25.PubMedCrossRefGoogle Scholar
  5. 5.
    Rieger-Christ KM, Mourtzinos A, Lee PJ, Zagha RM, Cain J, Silverman M, et al. Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection. Cancer. 2003;98:737–44.PubMedCrossRefGoogle Scholar
  6. 6.
    van Rhijn BW, Lurkin I, Radvanyi F, Kirkels WJ, van der Kwast TH, Zwarthoff EC. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res. 2001;61:1265–8.PubMedGoogle Scholar
  7. 7.
    Bakkar AA, Wallerand H, Radvanyi F, Lahaye JB, Pissard S, Lecerf L, et al. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res. 2003;63:8108–12.PubMedGoogle Scholar
  8. 8.
    Slaton JW, Benedict WF, Dinney CP. P53 in bladder cancer: mechanism of action, prognostic value, and target for therapy. Urology. 2001;57:852–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT, et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature. 1999;398:714–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Yang A, Walker N, Bronson R, Kaghad M, Oosterwegel M, Bonnin J, et al. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature. 2000;404:99–103.PubMedCrossRefGoogle Scholar
  11. 11.
    Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408:307–10.PubMedCrossRefGoogle Scholar
  12. 12.
    Benard J, Douc-Rasy S, Ahomadegbe JC. TP53 family members and human cancers. Hum Mutat. 2003;21:182–91.PubMedCrossRefGoogle Scholar
  13. 13.
    Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V, et al. p63, a p53 homolog at 3q27–29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell. 1998;2:305–16.PubMedCrossRefGoogle Scholar
  14. 14.
    Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell. 1997;90:809–19.PubMedCrossRefGoogle Scholar
  15. 15.
    Khoury MP, Bourdon JC. The isoforms of the p53 protein. Cold Spring Harb Perspect Biol. 2010;2:a000927.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Zigeuner R, Tsybrovskyy O, Ratschek M, Rehak P, Lipsky K, Langner C. Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma. Urology. 2004;63:1079–83.PubMedCrossRefGoogle Scholar
  17. 17.
    Gu X, Coates PJ, Boldrup L, Nylander K. p63 contributes to cell invasion and migration in squamous cell carcinoma of the head and neck. Cancer Lett. 2008;263:26–34.PubMedCrossRefGoogle Scholar
  18. 18.
    Lo Muzio L, Santarelli A, Caltabiano R, Rubini C, Pieramici T, Trevisiol L, et al. p63 overexpression associates with poor prognosis in head and neck squamous cell carcinoma. Hum Pathol. 2005;36:187–94.PubMedCrossRefGoogle Scholar
  19. 19.
    Urist MJ, Di Como CJ, Lu ML, Charytonowicz E, Verbel D, Crum CP, et al. Loss of p63 expression is associated with tumor progression in bladder cancer. Am J Pathol. 2002;161:1199–206.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Moll UM. The Role of p63 and p73 in tumor formation and progression: coming of age toward clinical usefulness. Clin Cancer Res. 2003;9:5437–41.Google Scholar
  21. 21.
    Chi SG, Chang SG, Lee SJ, Lee CH, Kim JI, Park JH. Elevated and biallelic expression of p73 is associated with progression of human bladder cancer. Cancer Res. 1999;59:2791–3.PubMedGoogle Scholar
  22. 22.
    Symonds H, Krall L, Remington L, Saenz-Robles M, Lowe S, Jacks T, et al. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell. 1994;78:703–11.PubMedCrossRefGoogle Scholar
  23. 23.
    De Laurenzi V, Melino G. Evolution of functions within the p53/p63/p73 family. Ann N Y Acad Sci. 2000;926:90–100.PubMedCrossRefGoogle Scholar
  24. 24.
    Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen SC, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med. 1994;331:1259–64.PubMedCrossRefGoogle Scholar
  25. 25.
    Sigal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res. 2000;60:6788–93.PubMedGoogle Scholar
  26. 26.
    George B, Datar RH, Wu L, Cai J, Patten N, Beil SJ, et al. p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer. J Clin Oncol. 2007;25:5352–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Lu ML, Wikman F, Orntoft TF, Charytonowicz E, Rabbani F, Zhang Z, et al. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods. Clin Cancer Res. 2002;8:171–9.PubMedGoogle Scholar
  28. 28.
    de Magalhaes JP, Curado J, Church GM. Meta-analysis of age-related gene expression profiles identifies common signatures of aging. Bioinformatics. 2009;25:875–81.PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Yang X, Lu H, Yan B, Romano RA, Bian Y, Friedman J, et al. DeltaNp63 versatilely regulates a Broad NF-kappaB gene program and promotes squamous epithelial proliferation, migration, and inflammation. Cancer Res. 2011;71:3688–700.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Koga F, Kawakami S, Fujii Y, Saito K, Ohtsuka Y, Iwai A, et al. Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clin Cancer Res. 2003;9:5501–7.PubMedGoogle Scholar
  31. 31.
    Yokomizo A, Mai M, Tindall DJ, Cheng L, Bostwick DG, Naito S, et al. Overexpression of the wild type p73 gene in human bladder cancer. Oncogene. 1999;18:1629–33.PubMedCrossRefGoogle Scholar
  32. 32.
    Sun XF. p73 overexpression is a prognostic factor in patients with colorectal adenocarcinoma. Clin Cancer Res. 2002;8:165–70.PubMedGoogle Scholar
  33. 33.
    Soldevilla B, Diaz R, Silva J, Campos-Martin Y, Munoz C, Garcia V, et al. Prognostic impact of DeltaTAp73 isoform levels and their target genes in colon cancer patients. Clin Cancer Res. 2011;17:6029–39.PubMedCrossRefGoogle Scholar
  34. 34.
    Dominguez G, Garcia JM, Pena C, Silva J, Garcia V, Martinez L, et al. DeltaTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1. J Clin Oncol. 2006;24:805–15.PubMedCrossRefGoogle Scholar
  35. 35.
    Efeyan A, Serrano M. p53: guardian of the genome and policeman of the oncogenes. Cell Cycle. 2007;6:1006–10.PubMedCrossRefGoogle Scholar
  36. 36.
    Waltermann A, Kartasheva NN, Dobbelstein M. Differential regulation of p63 and p73 expression. Oncogene. 2003;22:5686–93.PubMedCrossRefGoogle Scholar
  37. 37.
    Dekairelle AF, Tombal B, Cosyns JP, Gala JL. Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder. Clin Cancer Res. 2005;11:4724–32.PubMedCrossRefGoogle Scholar
  38. 38.
    Puig P, Capodieci P, Drobnjak M, Verbel D, Prives C, Cordon-Cardo C, et al. p73 Expression in human normal and tumor tissues: loss of p73alpha expression is associated with tumor progression in bladder cancer. Clin Cancer Res. 2003;9:5642–51.PubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Danae Papadogianni
    • 1
  • Nikolaos Soulitzis
    • 1
  • Demetrios Delakas
    • 2
  • Demetrios A. Spandidos
    • 1
  1. 1.Laboratory of Clinical Virology, Medical SchoolUniversity of CreteHeraklionGreece
  2. 2.Department of UrologyAsklipeiion HospitalAthensGreece

Personalised recommendations